"11" Result
Sort By:
Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the correct purchasers, the drug will fail to reach its i…
"Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"--
"Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"--
"The major advances in the field of biotechnology and molecular biology in the 21st century have led to a better understanding of the pathophysiology of several diseases. A new generation of biopharmaceuticals has emerged, including a wide and heterogeneous range of innovative c…
The major advances in the field of biotechnology and molecular biology in thetwenty-first century have led to a better understanding of the pathophysiology of diseases. A new generation of biopharmaceuticals has emerged, including a wide and heterogeneous range of innovative cel…